GT Biopharma (GTBP) Stock Price, News & Analysis

Company Overview

GT Biopharma, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research centers on natural killer (NK) cells, a component of the immune system that can recognize and destroy abnormal cells.

GT Biopharma’s principal technology is its TriKE (trispecific killer engager) platform. These engineered molecules are designed to bind a cancer-associated target, activate NK cells through the CD16 receptor, and enhance NK-cell activity through an interleukin-15 component. The company has applied this approach to blood cancers, including acute myeloid leukemia and other hematologic malignancies.

The company has advanced investigational programs such as GTB-3550, an NK-cell engager designed to target CD33-expressing cancer cells, along with additional programs directed at targets including CD33 and CD19. GT Biopharma’s development activities have primarily focused on clinical and preclinical oncology research in the United States. Its therapies remain investigational and require further clinical evaluation to establish their safety and effectiveness.

Key Stats

• Today's Range: $3.71 to $4.24
• 50-Day Range: $3.84 to $11.63
• 52-Week Range: $3.71 to $28.75
• Volume: 75,115 shs
• Average Volume: 74,105 shs
• Market Capitalization: $7.91 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

GT Biopharma Stock Analysis - MarketRank™

GT Biopharma scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

GT Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

GT Biopharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

GT Biopharma has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

12.09% of the float of GT Biopharma has been sold short.

Short Interest Ratio / Days to Cover

GT Biopharma has a short interest ratio ("days to cover") of 3.21, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GT Biopharma has recently decreased by 11.59%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GT Biopharma does not currently pay a dividend.

Dividend Growth

GT Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.37

News Sentiment

GT Biopharma has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for GT Biopharma this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for GTBP on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added GT Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GT Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.11% of the stock of GT Biopharma is held by insiders.

Percentage Held by Institutions

8.15% of the stock of GT Biopharma is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 11/12/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GTBP
• Previous Symbol: OTCMKTS:OXISD
• CIK: 109657
• Web: www.gtbiopharma.com
• Phone: (800) 304-9888
• Fax: N/A
• Employees: 1
• Year Founded: 1965

Profitability

• EPS (Trailing Twelve Months): ($147.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$28.35 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -213.16%
• Return on Assets: -150.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.61
• Quick Ratio: 2.61

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: $0.36 per share
• Price / Cash Flow: 10.56
• Book Value: $5.66 per share
• Price / Book: 0.68

Miscellaneous

• Outstanding Shares: 2,060,000
• Free Float: 2,038,000
• Market Cap: $7.91 million
• Optionable: No Data
• Beta: 0.88